Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Yao JC, et al. Among authors: pavel me. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. N Engl J Med. 2011. PMID: 21306238 Free PMC article. Clinical Trial.
ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors.
Pavel M, Grossman A, Arnold R, Perren A, Kaltsas G, Steinmüller T, de Herder W, Nikou G, Plöckinger U, Lopes JM, Sasano H, Buscombe J, Lind P, O'Toole D, Oberg K; Palma de Mallorca Consensus Conference Participants. Pavel M, et al. Neuroendocrinology. 2010;91(4):326-32. doi: 10.1159/000287277. Epub 2010 May 6. Neuroendocrinology. 2010. PMID: 20453466 Free article. No abstract available.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Pavel ME, et al. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25. Lancet. 2011. PMID: 22119496 Clinical Trial.
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R; Barcelona Consensus Conference participants. Jensen RT, et al. Neuroendocrinology. 2012;95(2):98-119. doi: 10.1159/000335591. Epub 2012 Feb 15. Neuroendocrinology. 2012. PMID: 22261919 Free PMC article. No abstract available.
Research and innovation in the development of everolimus for oncology.
Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ. Lebwohl D, et al. Expert Opin Drug Discov. 2011 Mar;6(3):323-38. doi: 10.1517/17460441.2011.558079. Epub 2011 Feb 17. Expert Opin Drug Discov. 2011. PMID: 22647206
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. Among authors: pavel m. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
Consensus on biomarkers for neuroendocrine tumour disease.
Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Oberg K, et al. Lancet Oncol. 2015 Sep;16(9):e435-e446. doi: 10.1016/S1470-2045(15)00186-2. Lancet Oncol. 2015. PMID: 26370353 Free PMC article. Review.
207 results